Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy.
Hodgkin Lymphoma
BIOLOGICAL: AFM13|BIOLOGICAL: Pembrolizumab
Number of participants experiencing dose limiting toxicity (DLT) during combination treatment, Up to 9 months
Number and frequency of adverse events, Up to 30 months|Objective response rate (ORR), Up to 30 months
The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy.